Novel Therapeutic Strategy Targets Aggressive Triple-Negative Breast Cancer Through ATR and PKMYT1 Co-Inhibition
Houston, TX – december 26, 2025 – A groundbreaking study published today in Science Translational Medicine details a significant therapeutic vulnerability in patients diagnosed with an aggressive subtype of triple-negative breast cancer. Researchers at The University of Texas MD Anderson Cancer Center, led by Dr.Khandan Keyomarsi, have identified a strategy involving the simultaneous inhibition of ATR and PKMYT1 that triggers cancer cell death in models lacking the Rb1 gene. This discovery offers a promising new avenue for treatment, particularly for patients who have not responded to conventional therapies.
Triple-negative breast cancer is known for its aggressive nature and limited treatment options. This research focuses on a specific subset of these cancers characterized by Rb1 deficiency – a loss of function in the Rb1 gene, which plays a crucial role in regulating cell division and maintaining genomic stability. The study demonstrates that this deficiency creates a unique vulnerability that can be exploited through targeted therapy.
Unlocking Synthetic Lethality: How Rb1 Deficiency Creates a Therapeutic Opportunity
The research team employed genomic profiling, proteomics, and patient-derived xenografts to reveal that Rb1-deficient tumors exhibit disrupted DNA repair processes. Consequently, these cancer cells become heavily reliant on the ATR and PKMYT1 pathways to survive. By simultaneously inhibiting these two proteins – both essential for maintaining genomic stability during cell division – researchers induced a catastrophic accumulation of DNA damage, ultimately leading to apoptosis (programmed cell death), tumor shrinkage, and improved survival rates in preclinical models.
“This is a breakthrough discovery,” explains Dr. Keyomarsi, professor of Experimental Radiation Oncology. “Rb1-deficient tumors do not respond to CDK4/6 inhibitors as they depend on Rb1 to regulate cell division. But that same deficiency makes them vulnerable to ATR and PKMYT1 inhibition. We can now identify patients who may benefit from an entirely different therapeutic strategy.”
This approach leverages a concept known as “synthetic lethality.” While mutations can drive cancer development, cancer cells also require the ability to replicate.If these cells accumulate to many mutations during replication, they lose functionality. The strategy intentionally overwhelms the cancer cell’s capacity to correct DNA errors, inducing cell death.Inhibiting ATR and PKMYT1 effectively accelerates this process, causing an overload of mutations and triggering apoptosis.
Rb1 Deficiency: A Dual Role in Resistance and Vulnerability
The study highlights the paradoxical role of Rb1 deficiency. While the loss of Rb1 contributes to uncontrolled cell division and resistance to CDK4/6 inhibitors – a common class of breast cancer drugs – it simultaneously creates a critical vulnerability. The reliance on ATR and PKMYT1 for survival in Rb1-deficient cells provides a specific target for therapeutic intervention.
Clinical Translation and Future Directions
The findings hold significant promise for near-term clinical submission. Several ATR and PKMYT1 inhibitors are already undergoing clinical trials, with some receiving fast-track designation from the Food and Drug Governance (FDA). The Phase I MYTHIC Trial, led by MD Anderson researchers, is currently evaluating the combination of these inhibitors in patients with specific mutations in solid tumors.
The current research will directly inform the development of Rb1-based biomarker strategies to identify patients most likely to respond to dual ATR/PKMYT1 inhibition. furthermore, Dr. Keyomarsi notes that Rb1 deficiency may also predict sensitivity to other DNA-damaging therapies, such as chemotherapy and radiation.
“Incorporating Rb1 status into clinical decision-making could help tailor more effective, personalized treatment plans for patients with triple-negative breast cancer,” Dr. Keyomarsi concludes. This research represents a significant step forward in the fight against this aggressive disease, offering hope for improved outcomes and a more targeted approach to cancer therapy.